INN

Human medicines European public assessment report (EPAR): Vidaza, azacitidine, Date of authorisation: 17/12/2008, Revision: 27, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Liver, Marketing, INN, Risk, Leukopenia, Woman, Nausea, DNA, Cancer, Death, Anatomy, Pancreatic serous cystadenoma, IIA, CHMP, Skin, Bone marrow, ATC, IPSS, Myeloid tissue, European, Ageing, MDS, Abdomen, Kidney, Neutrophil, Blood, Syndrome, Thigh, Patient, RNA, Medical Subject Headings, European Commission, WHO, B cell, International, Neutropenia, Language, CMML, Myelodysplastic syndrome, Thrombocytopenia, Monocyte, Select, HSCT, Medicine, Vomiting, Cytidine, Survival, Classification, Stomach, Myelocyte, Growth, Committee, AML, Acute leukemia, Medical device

Human medicines European public assessment report (EPAR): Vidaza, azacitidine, Date of authorisation: 17/12/2008, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vidaza, azacitidine, Date of authorisation: 17/12/2008, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Ivozall, clofarabine, Date of authorisation: 14/11/2019, Revision: 5, Status: Withdrawn

Retrieved on: 
Dienstag, Januar 2, 2024
Medical Subject Headings, Marketing, Acute leukemia, INN, ATC, International, Language, Clofarabine, Safety, Select, Patient, Diagnosis, ALL, Anatomy, IIA, Medical device

Overview

Key Points: 
  • Overview
    Ivozall : EPAR - Medicine overview
    Product information
    Ivozall : EPAR - Product Information
    Latest procedure affecting product information: IB/0006
    06/03/2023
    This medicine’s product information is available in all official EU languages.
  • Select 'available languages' to access the language you need.
  • Product information documents contain:
    - summary of product characteristics (annex I);
    - manufacturing authorisation holder responsible for batch release (annex IIA);
    - conditions of the marketing authorisation (annex IIB);
    - labelling (annex IIIA);
    - package leaflet (annex IIIB).
  • Assessment history
    This page was last updated on

Human medicines European public assessment report (EPAR): Entresto, sacubitril,valsartan, Date of authorisation: 19/11/2015, Revision: 19, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Blood pressure, Urine, Patient, Medical Subject Headings, Heart failure, Marketing, Nitrosamine, Quality of life, Kidney, Sacubitril, INN, Pediatrics, Natriuresis, Death, Valsartan, Woman, Failure, Hypotension, ATC, System, Blood, International, Sodium, European, Disease, Angioedema, Diabetes, Tissue, Profile, Language, Ageing, Mouth, Heart, Enalapril, Hyperkalemia, Angiotensin, Water, European Medicines Agency, ACE, Tablet, Select, Liver disease, Anatomy, Medicine, Fibrosis, IIA, Science, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Entresto, sacubitril,valsartan, Date of authorisation: 19/11/2015, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Entresto, sacubitril,valsartan, Date of authorisation: 19/11/2015, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 3, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
IOP, Medical Subject Headings, Marketing, Pupil, INN, ATC, Paratriathlon, Bleeding, International, Drainage, Iris, Ocular hypertension, Disease, Language, Brain, Eye, Timolol, European Medicines Agency, Select, Rho, Patient, Vein, Safety, Anatomy, Retina, IIA, Pressure, Optic nerve, Erythema, Medical device

Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 28, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Urine, Liver, Medical Subject Headings, Fungal infection, Marketing, European Commission, INN, Stomach, Allergy, Itraconazole, Saquinavir, ATC, Glass, Nelfinavir, Depression, Kidney disease, Bleeding, International, European, Megacolon, Disease, Urinary retention, Language, Muscle weakness, Urinary bladder, Inflammation, Nefazodone, Water, Peanut, Ulcerative colitis, Colitis, Ketoconazole, Ritonavir, Tablet, Hyperkinesia, Indinavir, CYP3A4, Xerostomia, Select, Committee, Urination, Patient, Liver disease, Atazanavir, Anatomy, Medicine, Clarithromycin, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 28, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 19, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Blood pressure, Urine, Patient, Medical Subject Headings, Heart failure, Marketing, Nitrosamine, Quality of life, Kidney, Sacubitril, INN, Pediatrics, Natriuresis, Death, Valsartan, Woman, Failure, Hypotension, ATC, System, Blood, International, Sodium, European, Disease, Angioedema, Tissue, Profile, Diabetes, Language, Ageing, Heart, Enalapril, Angiotensin, Hyperkalemia, Water, European Medicines Agency, ACE, Tablet, Select, Liver disease, Anatomy, Medicine, Fibrosis, IIA, Science, Medical device

Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Spravato, esketamine, Date of authorisation: 18/12/2019, Revision: 9, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Blood pressure, Patient, Medical Subject Headings, Marketing, DSM-IV codes, INN, Risk, Rupture, ATC, Depression, System, Bleeding, International, Headache, Nausea, Language, Brain, Dizziness, Vertigo, MADRS, Emotion, European Medicines Agency, Select, Cell, Overalls, Safety, NMDA, Anatomy, Somnolence, SSRI, IIA, SNRI, Dysgeusia, Hypoesthesia, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Spravato, esketamine, Date of authorisation: 18/12/2019, Revision: 9, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Spravato, esketamine, Date of authorisation: 18/12/2019, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Date of authorisation: 09/03/2004, Revision: 24, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Liver, Medical Subject Headings, Diarrhea, Marketing, European Commission, Stomatitis, Agency, INN, Breast, HER2, Fatigue, Woman, Breast cancer, ATC, Pain, LHRH, International, Platelet, Syringe, European, Injection, Weakness, Nausea, Blood, Language, Neoplasm, Mouth, Cancer, Inflammation, European Medicines Agency, Infection, Growth, Select, Cell, Patient, Liver disease, Time, Anatomy, Medicine, IIA, Birth control

Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Date of authorisation: 09/03/2004, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Date of authorisation: 09/03/2004, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Atriance, nelarabine, Date of authorisation: 22/08/2007, Revision: 27, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Marketing, INN, Risk, Constipation, Needle, Body surface area, Nausea, DNA, Cancer, T-ALL, Anatomy, Paresthesia, Cough, IIA, Hypoesthesia, Diarrhea, Fever, Fatigue, Infection, Bone marrow, ATC, Pain, Disease, Ageing, Somnolence, Periodic breathing, Cerebral edema, Edema, Enzyme, Safety, Anemia, Tumor lysis syndrome, Patient, Medical Subject Headings, Febrile neutropenia, Agency, Guanine, International, Paralysis, LBL, Neutropenia, Blood, Language, Myalgia, Dizziness, Thrombocytopenia, Nervous system, Thymus, Select, Vomiting, Peripheral neuropathy, Survival, Lymph, Extremities, System, Weakness, Headache, Brain, Swelling, European Medicines Agency, Convulsion, Growth, Cell, Lymphatic system, Medical device

Human medicines European public assessment report (EPAR): Atriance, nelarabine, Date of authorisation: 22/08/2007, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Atriance, nelarabine, Date of authorisation: 22/08/2007, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Marketing, INN, Risk, MPA, Shivering, CD20, PML, ACR20, Pemphigus vulgaris, Cancer, Inflammation, Death, Infection, Anatomy, IIA, Skin, Chills, Fever, ATC, Bone marrow, GPA, Disease, Allergy, Hepatitis B virus, CLL, NHL, Safety, Arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Antibody, Vincristine, International, Language, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, Encephalitis, Medicine, B cell, Prednisolone, Autoimmune disease, CHOP, Blood, Rheumatoid arthritis, Vasculitis, European Medicines Agency, Doxorubicin, Cell, Chronic lymphocytic leukemia, Resuscitation, Medical device

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised